Table 1.
Description of publicly available studies used in the meta-analysis
| Reference ID | Sample size | Gene expression analysis and validation analysis platforms |
|---|---|---|
| [31] | 6 hemangiomas and 7 normal term placental tissues | U95Av2 GeneChip oligonucleotide microarrays (Affymetrix) |
| [32] | 7 hemangiomas (3 proliferating, 4 involuting) and 3 normal term placental tissues | Human Genome U133 Plus 2.0 (Affymetrix) |
| [33] | 4 pairs of early proliferative stage and spontaneously early involution stage of the same hemangiomas, 11 hemangiomas (6 proliferative and 5 involuting), 5 controls (normal skin) Serum from 69 patients with hemangioma (46 proliferative and 23 involuting), 20 patients with venous malformations and 31 negative controls (children with cheilopalatognathus) | Illumina Human-6 bead chip, QRT-PCR |
| [34] GSE43742 | HEMECs, HDMVECs, 16 infantile hemangioma, 4 normal controls (neonatal foreskin) | Illumina HumanHT-12 V4.0 expression beadchip Immunohistochemistry |
| [35] | hemSCs, bm-MPCs, HDMECs, cbEPCs and abEPCs | RQ-PCR, Functional assays, Immunofluorescence |
| [36] | HemSCs, HemECs, HDMECs and MSCs | RQ-PCR, Immunofluorescence |
| [37] | 48 hemangiomas, 9 vascular malformations and vascular tumor specimens, 11 neonatal foreskin controls and HemECs from proliferating hemangioma | GeneFilter GF211 (Invitrogen) |
QRT-PCR quantitative reverse-transcription polymerase chain reaction, HEMECs infantile hemangioma endothelial cells, HDMVECs dermal microvascular endothelial cells, HemECs hemangioma-derived endothelial cells, hemSCs proliferating hemangioma-derived CD133+ cells, HDMECs human dermal microvascular endothelial cells, cbEPCs cord blood endothelial progenitor cells, abEPCs adult blood endothelial progenitor cells, bm-MPCs bone marrow-mesenchymal progenitor cells, HemSCs hemangioma-derived stem cells, MSCs mesenchymal stem cells